Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

bd844a66-bb61-4ba1-9301-1bdeec35620f

bdf66a36-189a-5189-8543-f193781f26fe

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
age_years
41

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.300
  • PANCREAS_BETA_CELLS+0.290
  • BILE_ACID_METABOLISM+0.140
  • DNA_REPAIR+0.120
  • PEROXISOME+0.110
  • MYC_TARGETS_V2+0.090
  • ADIPOGENESIS+0.080
  • XENOBIOTIC_METABOLISM+0.070
  • KRAS_SIGNALING_DN+0.020
  • MYC_TARGETS_V1+0.000

Top 10 suppressed

  • ANGIOGENESIS-0.600
  • INTERFERON_ALPHA_RESPONSE-0.520
  • INTERFERON_GAMMA_RESPONSE-0.490
  • TNFA_SIGNALING_VIA_NFKB-0.450
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
  • HYPOXIA-0.360
  • ALLOGRAFT_REJECTION-0.330
  • HEDGEHOG_SIGNALING-0.330
  • INFLAMMATORY_RESPONSE-0.320
  • TGF_BETA_SIGNALING-0.320

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-55-6972-01A-11R-1949-07
lung-landscapes@6
cohortA20.907
2TCGA-E5-A4U1-01A-11R-A31N-07
bladder-landscape@3
0.890
3SRR8518209
breast-umap@18
C0.886
4TCGA-LL-A6FP-01A-11R-A31O-07
breast-umap@18
B0.886
5cf2834ac-00ed-4372-be25-042f38241196
melanoma-umap@29
0.885
6TCGA-DK-AA75-01A-11R-A39I-07
bladder-landscape@3
0.884
7R16
bladder-landscape@3
0.884
8s0112301
melanoma-umap@29
0.880
9MDT-AP-2119
medullo-epn-umap@date-based
MedMedulloblastoma0.879
10SRR4296068
lung-landscapes@6
cohortA10.876

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 9 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.300Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.290Cobimetinib— uncovered
BILE_ACID_METABOLISM0.140Inavolisib— uncovered
DNA_REPAIR0.120Idelalisib— uncovered
PEROXISOME0.110Idelalisib— uncovered
MYC_TARGETS_V20.090Idelalisib— uncovered
ADIPOGENESIS0.080Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.070Inavolisib— uncovered
KRAS_SIGNALING_DN0.020Remibrutinib— uncovered